Biohaven Ltd. (NYSE:BHVN - Get Free Report) was the target of some unusual options trading on Tuesday. Stock traders acquired 7,638 call options on the stock. This represents an increase of approximately 588% compared to the typical volume of 1,110 call options.
Biohaven Price Performance
BHVN stock traded down $3.60 during mid-day trading on Friday, reaching $19.81. The company had a trading volume of 6,163,647 shares, compared to its average volume of 1,130,618. The company has a market capitalization of $2.02 billion, a PE ratio of -2.12 and a beta of 1.33. The firm has a 50 day moving average of $26.44 and a 200 day moving average of $37.51. Biohaven has a 12 month low of $15.79 and a 12 month high of $55.70.
Biohaven (NYSE:BHVN - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.29). Analysts anticipate that Biohaven will post -8.9 EPS for the current year.
Insider Buying and Selling at Biohaven
In other Biohaven news, Director John W. Childs purchased 32,700 shares of the firm's stock in a transaction that occurred on Tuesday, March 4th. The shares were bought at an average price of $30.47 per share, with a total value of $996,369.00. Following the completion of the purchase, the director now directly owns 2,320,571 shares in the company, valued at $70,707,798.37. This trade represents a 1.43 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 16.00% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Biohaven
Several institutional investors have recently made changes to their positions in BHVN. Peregrine Capital Management LLC grew its holdings in Biohaven by 3.3% during the 1st quarter. Peregrine Capital Management LLC now owns 153,825 shares of the company's stock worth $3,698,000 after acquiring an additional 4,946 shares in the last quarter. KBC Group NV lifted its position in shares of Biohaven by 35.0% in the 1st quarter. KBC Group NV now owns 4,560 shares of the company's stock worth $110,000 after purchasing an additional 1,183 shares during the period. SG Americas Securities LLC increased its holdings in Biohaven by 155.8% during the first quarter. SG Americas Securities LLC now owns 23,029 shares of the company's stock valued at $554,000 after buying an additional 14,028 shares during the period. Weybosset Research & Management LLC increased its holdings in Biohaven by 23.7% during the first quarter. Weybosset Research & Management LLC now owns 16,880 shares of the company's stock valued at $406,000 after buying an additional 3,235 shares during the period. Finally, Rhumbline Advisers lifted its holdings in Biohaven by 6.2% during the first quarter. Rhumbline Advisers now owns 124,839 shares of the company's stock worth $3,001,000 after buying an additional 7,244 shares during the period. Hedge funds and other institutional investors own 88.78% of the company's stock.
Wall Street Analyst Weigh In
A number of research analysts recently commented on BHVN shares. JPMorgan Chase & Co. lowered their price target on shares of Biohaven from $72.00 to $68.00 and set an "overweight" rating for the company in a report on Wednesday, March 5th. Morgan Stanley lowered their price objective on Biohaven from $69.00 to $63.00 and set an "overweight" rating for the company in a research note on Friday, March 7th. Deutsche Bank Aktiengesellschaft set a $60.00 target price on Biohaven and gave the company a "buy" rating in a research report on Thursday, March 20th. HC Wainwright restated a "buy" rating and set a $54.00 price target on shares of Biohaven in a report on Tuesday, March 4th. Finally, William Blair upgraded shares of Biohaven to a "strong-buy" rating in a research report on Thursday. Fourteen analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $62.77.
Check Out Our Latest Stock Analysis on Biohaven
Biohaven Company Profile
(
Get Free Report)
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.
See Also
Before you consider Biohaven, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biohaven wasn't on the list.
While Biohaven currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
